Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model

Breast Cancer Research

Table 2 p-EGFR expression status in tumor and stroma of non-IBC patient samples

	p-EGFR expression status in tumor: No. of patients (%)			p-EGFR expression status in stroma: No. of patients (%)
	Negative	Positive	P	Negative	Positive	P
ER expression
Negative	0 (0.0)	12 (100.0)	0.949	0 (0.0)	13 (100.0)	0.437
Positive	0 (0.0)	8 (100.0)		0 (0.0)	11 (100.0)
PR expression
Negative	0 (0.0)	13 (100.0)	0.546	0 (0.0)	15 (100.0)	0.565
Positive	0 (0.0)	7 (100.0)		0 (0.0)	9 (100.0)
HER2 expression
Negative	0 (0.0)	14 (100.0)	0.598	0 (0.0)	15 (100.0)	0.285
Positive	0 (0.0)	4 (100.0)		0 (0.0)	7 (100.0)
Triple-negative status
No	0 (0.0)	15 (100.0)	0.787	0 (0.0)	19 (100.0)	0.410
Yes	0 (0.0)	3 (100.0)		0 (0.0)	3 (100.0)

p-EGFR, phospho-epidermal growth factor receptor; IBC, inflammatory breast cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

ISSN: 1465-542X